Reckitt Benckiser Group plc (RBGPF)
NEUTRALFundamental
52
Price
$5150.00
Market Cap
$32.48B
Part 1 · What the company is worth
Overview
Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.
How it makes money
Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.
Competitive moat
Brand · NarrowReckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.
What drives demand
DefensiveMost of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.
The case for
Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.
The case against
Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.
Written by the editors, published on August 18, 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$13.35B
Trailing 12 months to the last reported quarter — estimated from per-share metrics
Net Income
$2.81B
Trailing 12 months to the last reported quarter — estimated from per-share metrics
Free Cash Flow
$3.09B
Total Equity
$5.67B
Total Liabilities
$10.25B
Current Ratio
0.59
Interest Coverage
-
Debt/EBITDA
2.86
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$2156.36
Current Price
$5150.00
Margin of Safety
-138.8%
Fair Value Range
$1401.63 - $2911.08
Estimation Methods
Valuation Metrics
P/E Ratio
1169.99
ROE
48.0%
P/B Ratio
580.17
P/FCF
1049.76
Gross Margin
59.6%
ROIC
12.3%
Profitability Radar
Value Creation (Economic Moat)
ROIC
12.3%
WACC
8.5%
ROIC − WACC
+3.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (10)
- ROIC 12.3%
- Gross Margin 59.6%
- Debt/Equity ratio
- Operating Margin 28.5%
- Positive Free Cash Flow
- Debt/EBITDA
- ROE 42.9%
- Analyst Consensus 76% Buy
- PEG Ratio 0.47
- Net Margin Trend 22.4% vs 10.1%
Failed (11)
- Price CAGR -3.27%
- P/FCF 1049.76
- P/B Ratio 580.17
- CapEx intensity
- Current Ratio
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 0.3%
- Earnings Surprise avg 2.4%
- Earnings Quality (OCF/NI) 0.66
- Piotroski F-Score 1/9
Unavailable (6)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Share Dilution (missing shares data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Moderate: some gap between profits and cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Kristoffer Loe Licht | CEO & Executive Director | 49 |
| Ms. Shannon Sue Eisenhardt | CFO & Executive Director | 51 |
| Mr. Nicholas James Ashworth C.F.A. | Senior Vice President of Investor Relations | - |
| Ms. Catheryn O'Rourke | Senior VP, General Counsel & Company Secretary | 52 |
| Ms. Sheila Redzepi | Chief Communications & Corporate Affairs Officer | 46 |
| Mr. Ranjay Radhakrishnan | Chief Human Resources Officer | 54 |
| Mr. Jerome Lemaire | President North America | 51 |
| Ms. Angela Naef Ph.D. | Chief Research & Development Officer | 49 |
| Ms. Susan Sholtis | President of Nutrition | 58 |
| Dr. Alessio Fasano M.D. | Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business | - |
Audit Risk
4
Board Risk
2
Compensation Risk
3
Shareholder Rights Risk
1
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for RBGPF, sourced from Markets Gazette.